Catabasis Pharmaceuticals, Inc. CATB
8.54 0.00 (+0.00%)
At closeSep 9, 2021, 12:00 AM EDT
8.48 Day range 9.21
52-week range unavailable
- Market cap
- 234.86M
- Shares out
- 12.82M
- Forward P/E
- -2.81
- Volume
- 98.87K
- Open
- 10.07
- Previous close
- 8.54
- Day's range
- 8.48 – 9.21
- Beta
- 1.66
- Analysts
- Strong Buy
- Price target
- 23.00 (+169.3%)
- Earnings date
- Aug 9, 2021
No chart data for this range yet.
Key statistics
- Enterprise value
- 78.69M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -18.44M
- Total cash
- 139.52M
- Total debt
- 713.00K
- Return on equity
- -210.26%
- Short % of float
- 0.78%
- 50-day average
- 8.23
- 200-day average
- 3.74
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 23.00 +169.3% upside
Now 8.54
- Target (low)
- 13.00
- Target (mean)
- 23.00
- Target (high)
- 36.00
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy2
- Buy1
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 9, 2021
Expected Aug 9, 2021. Consensus EPS estimate -0.77.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2021 | Jun 1, 2021 | -1.56 | — | — | — |
| May 13, 2021 | Mar 1, 2021 | -1.08 | — | — | — |
| Mar 11, 2021 | Dec 1, 2020 | -2.04 | — | — | — |
| Nov 12, 2020 | Sep 1, 2020 | -3.06 | — | — | — |
| Aug 10, 2020 | Jun 1, 2020 | -2.76 | — | — | — |
| May 12, 2020 | Mar 1, 2020 | -2.46 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 2, 2021 | Wedbush | init | — | Outperform |
| Aug 25, 2021 | HC Wainwright & Co. | up | Neutral | Buy |
| May 12, 2021 | Ladenburg Thalmann | init | — | Buy |
| Mar 11, 2021 | Oppenheimer | up | Perform | Outperform |
| Nov 2, 2020 | Wedbush | down | Outperform | Neutral |
| Oct 27, 2020 | Oppenheimer | down | Outperform | Perform |
About Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- catabasis.com
News
Catabasis Renames As Astria Therapeutics With New Disease Focus 
Stocks That Hit 52-Week Highs On Wednesday 
Catabasis Pharmaceuticals Shares: 1-For-6 Split Goes Into Effect 
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition 
CATB Stock Price Increases Over 40% Pre-Market: Why It Happened 
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences 
76 Biggest Movers From Yesterday 
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update 
60 Stocks Moving In Thursday's Mid-Day Session 
AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls
Your note
Sign in to keep a note on CATB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLARUS LIFESCIENCES II, L. P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2015 | 0 |
| DONOVAN JOANNE M. M.D., PH.D. | Officer | Conversion of Exercise of derivative security | Jun 29, 2015 | 409 |
| GALAKATOS NICHOLAS G | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2015 | 0 |
| GEORGE JEAN M | Director | Purchase | Jun 29, 2015 | 0 |
| JIROUSEK MICHAEL | Officer | Conversion of Exercise of derivative security | Jun 29, 2015 | 246,093 |
| LAUFER RON | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2015 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 1.67% | 1,281,200 | 16.22M | Jun 29, 2021 |
| RA Capital Management, L.P. | 1.29% | 991,312 | 12.55M | Jun 29, 2021 |
| Fairmount Funds Management LLC | 0.89% | 682,029 | 8.63M | Jun 29, 2021 |
| Cormorant Asset Management, LP | 0.77% | 591,668 | 7.49M | Jun 29, 2021 |
| VR Adviser, LLC | 0.70% | 539,001 | 6.82M | Jun 29, 2021 |
| Logos Global Management LP | 0.69% | 531,668 | 6.73M | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.11% | 85,675 | 1.08M | Jun 29, 2021 |
| Vanguard Extended Market Index Fund | 0.06% | 43,273 | 547.84K | Jun 29, 2021 |
| Fidelity Extended Market Index Fund | 0.02% | 19,055 | 241.24K | Jun 29, 2021 |
| Price (T.Rowe) Extended Equity Market Index Fund | 0.02% | 11,967 | 151.50K | Jun 29, 2021 |
| iShares Micro Cap ETF | 0.01% | 9,516 | 120.47K | Jun 29, 2021 |
| Schwab Capital Trust-Small Cap Index Fund | 0.01% | 7,602 | 102.63K | Apr 29, 2021 |